{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:46:47Z","timestamp":1788320807722,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Anna-Lisa and Sven Eric Lundgren Foundation for Medical Research."},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5nes universitetssjukhus","doi-asserted-by":"publisher","award":["92216"],"award-info":[{"award-number":["92216"]}],"id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adults with congenital heart disease (ACHD) are a group with an increased risk of thromboembolic complications and arrhythmias. Vitamin K antagonists are the most commonly used thromboprophylaxis therapy in this population. Studies on the efficacy and safety of novel oral anticoagulants (NOAC) are scare in ACHD. A retrospective study on ACHD patients on NOAC treatment registered in the National Quality Registry for Congenital Heart Disease, SWEDCON, and National Quality Registry for Atrial fibrillation and Anticoagulation, AuriculA, from Southern Sweden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty patients who had been taking NOAC treatment for a minimum of 3\u00a0months were included. Their median age was 55\u00a0years (SD 17\u00a0years) and 57% were male. Median follow-up was 17\u00a0months (IQR: 10\u201341). Eliquis was the most used NOAC (47%). Median CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score was 2 (IQR: 0\u20133) and HAS-BLED was 1 (IQR: 0\u20132). Complex ACHD was prevalent in 27% of the patients. No thromboembolic events were recorded; however, one major bleeding, unspecified, was reported during the total cumulative patient follow-up time of 64\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results of our study, although limited in size, suggest that NOAC appear safe and effective in ACHD patients. Further and larger studies on NOAC in ACHD patients are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-022-00326-1","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T04:28:49Z","timestamp":1673324929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel oral anticoagulant use in adults with congenital heart disease: a single-center experience report"],"prefix":"10.1186","volume":"75","author":[{"given":"Daniel","family":"Samarai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Isma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lindstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-7240","authenticated-orcid":false,"given":"Joanna","family":"Hlebowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"326_CR1","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1161\/CIRCULATIONAHA.115.011241","volume":"132","author":"J Lanz","year":"2015","unstructured":"Lanz J, Brophy JM, Therrien J, Kaouache M, Guo L, Marelli AJ (2015) Stroke in adults with congenital heart disease: incidence, cumulative risk, and predictors. Circulation 132:2385\u20132394. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.011241","journal-title":"Circulation"},{"key":"326_CR2","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/eurheartj\/ehq032","volume":"31","author":"CL Verheugt","year":"2010","unstructured":"Verheugt CL, Uiterwaal CSPM, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk APJ, Vliegen HW, Grobbee DE, Mulder BJM (2010) Mortality in adult congenital heart disease. Eur Heart J 31:1220\u20131229. https:\/\/doi.org\/10.1093\/eurheartj\/ehq032","journal-title":"Eur Heart J"},{"key":"326_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/CIRCOUTCOMES.114.000804","volume":"7","author":"Z Razouki","year":"2014","unstructured":"Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ (2014) Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes 7:664\u2013669. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.114.000804","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"326_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.thromres.2021.08.025","volume":"207","author":"D Samarai","year":"2021","unstructured":"Samarai D, Isma N, Lindstedt S, Hlebowicz J (2021) Quality and predictors of oral anticoagulation therapy with vitamin K antagonists in adult congenital heart disease: TTR and INR variability. Thromb Res 207:7\u20139. https:\/\/doi.org\/10.1016\/j.thromres.2021.08.025","journal-title":"Thromb Res"},{"key":"326_CR5","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.tru.2022.100122","volume":"9","author":"D Samarai","year":"2022","unstructured":"Samarai D, Lindstedt S, Isma N, Hlebowicz J (2022) Rate and risk factors for thromboembolism and major bleeding in adults with congenital heart disease taking vitamin K antagonist therapy. Thromb Res 9:100122. https:\/\/doi.org\/10.1016\/j.tru.2022.100122","journal-title":"Thromb Res"},{"issue":"6","key":"326_CR6","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/jcm9061794","volume":"9","author":"N Stalikas","year":"2020","unstructured":"Stalikas N, Doundoulakis I, Karagiannidis E, Bouras E, Kartas A, Frogoudaki A, Karvounis H, Dimopoulos K, Giannakoulas G (2020) Non-vitamin K oral anticoagulants in adults with congenital heart disease: a systematic review. J Clin Med 9(6):1794. https:\/\/doi.org\/10.3390\/jcm9061794","journal-title":"J Clin Med"},{"issue":"11","key":"326_CR7","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/europace\/euw295","volume":"18","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18(11):1609\u20131678. https:\/\/doi.org\/10.1093\/europace\/euw295","journal-title":"Europace"},{"issue":"5","key":"326_CR8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093\u20131100. https:\/\/doi.org\/10.1378\/chest.10-0134","journal-title":"Chest"},{"issue":"14","key":"326_CR9","doi-asserted-by":"publisher","first-page":"e637","DOI":"10.1161\/CIR.0000000000000602","volume":"139","author":"KK Stout","year":"2019","unstructured":"Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare GF (2019) 2018 AHA\/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on Clinical Practice Guidelines. J Am Coll Cardiol 139(14):e637\u2013e697. https:\/\/doi.org\/10.1161\/CIR.0000000000000602","journal-title":"J Am Coll Cardiol"},{"key":"326_CR10","doi-asserted-by":"publisher","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 133:257S-298S. https:\/\/doi.org\/10.1378\/chest.08-0674","journal-title":"Chest"},{"key":"326_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Subcommittee on Control of Anticoagulation of the, S., Standardization Committee of the International Society on, T. & Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"key":"326_CR12","unstructured":"Surveillance report (2017) Atrial fibrillation: management (2014) NICE guideline CG180"},{"key":"326_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/chd.12603","volume":"13","author":"J Georgekutty","year":"2018","unstructured":"Georgekutty J, Kazerouninia A, Wang YF, Ermis PR, Parekh DR, Franklin WJ, Lam WW (2018) Novel oral anticoagulant use in adult Fontan patients: a single center experience. Congenit Heart Dis 13:541\u2013547. https:\/\/doi.org\/10.1111\/chd.12603","journal-title":"Congenit Heart Dis"},{"key":"326_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijcard.2019.06.014","volume":"299","author":"H Yang","year":"2020","unstructured":"Yang H et al (2020) Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. Int J Cardiol 299:123\u2013130. https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.014","journal-title":"Int J Cardiol"},{"key":"326_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.amjcard.2015.10.062","volume":"117","author":"C Pujol","year":"2015","unstructured":"Pujol C, Niesert AC, Engelhardt A, Schoen P, Kusmenkov E, Pittrow D, Ewert P, Kaemmerer H (2015) Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J Cardiol 117:450\u2013455. https:\/\/doi.org\/10.1016\/j.amjcard.2015.10.062","journal-title":"Am J Cardiol"},{"key":"326_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.acvd.2018.04.003","volume":"111","author":"C Karsenty","year":"2018","unstructured":"Karsenty C, Zhao A, Marijon E, Ladouceur M (2018) Risk of thromboembolic complications in adult congenital heart disease: a literature review. Arch Cardiovasc Dis 111:613\u2013620. https:\/\/doi.org\/10.1016\/j.acvd.2018.04.003","journal-title":"Arch Cardiovasc Dis"},{"issue":"22","key":"326_CR17","doi-asserted-by":"publisher","first-page":"e021765","DOI":"10.1161\/JAHA.120.021765","volume":"10","author":"BW McCrindle","year":"2021","unstructured":"McCrindle BW, Michelson AD, Van Bergen AH, Suzana-Horowitz E, Pablo Sandoval J, Justino H, Harris KC, Jefferies JL, Miriam Pina L, Peluso C, Nessel K, Lu W, Li JS, UNIVERSE Study Investigators (2021) Thromboprophylaxis\u00a0for\u00a0children\u00a0post-fontan\u00a0procedure:\u00a0insights\u00a0from the\u00a0UNIVERSE\u00a0Study. J Am Heart Assoc 10(22):e021765. https:\/\/doi.org\/10.1161\/JAHA.120.021765","journal-title":"J Am Heart Assoc"},{"key":"326_CR18","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.acvd.2018.04.003","volume":"39","author":"AR Almutairi","year":"2017","unstructured":"Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH (2017) Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther 39:1456\u20131478. https:\/\/doi.org\/10.1016\/j.acvd.2018.04.003","journal-title":"Clin Ther"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-022-00326-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-022-00326-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-022-00326-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:20:36Z","timestamp":1673623236000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-022-00326-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["326"],"URL":"https:\/\/doi.org\/10.1186\/s43044-022-00326-1","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study ranged from 01\/01\/2006 to 23\/02\/2017 and involved all patients on oral anticoagulation treatment that were registered SWEDCON, the Swedish National Quality Registry for Congenital Heart Disease, in the South Region of Sweden (Region Sk\u00e5ne). All patients included in SWEDCON are in accordance with a waiver regarding written informed consent supported by the proper authorities. Written or verbal information are the only requirements on a national level.\u00a0The study was approved by the Regional Ethics Review Board in Lund, Sweden (Dnr 2017\/260). The investigation conforms to the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}